To include your compound in the COVID-19 Resource Center, submit it here.
A double-blind, U.S. Phase I trial in 20 healthy volunteers showed that high-dose IV PMX-30063 was
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury